TuHURA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2026, disclosing cash of $1.9 million, key clinical and regulatory updates, and two new U.S. patents, in a press release filed November 13, 2026.
Key Highlights
- Cash position: Cash and cash equivalents stood at $1.9 million as of September 30, 2026, with $9.2 million in gross proceeds received on the Parkview credit facility as of that date.
- R&D expenses: Research and development expenses were $3.7 million for the three months ended September 30, 2026, down from $5.0 million in the same period of 2025, a decrease of $1.3 million attributed to lower manufacturing costs.
- G&A expenses: General and administrative expenses were $2.0 million for Q3 2026, compared to $1.6 million for Q3 2025, an increase of $0.4 million driven primarily by non-cash stock compensation expense.
- Shares outstanding: Total common shares outstanding were approximately 65.8 million at September 30, 2026.
- FDA clearance: The company received an IND clearance and FDA "Study May Proceed" notice for TBS-2025, its VISTA-inhibiting antibody, in relapsed/refractory mutNPM1 acute myeloid leukemia.
- New patents: The company received a U.S. patent for its VISTA Inhibitor TBS-2025 extending to 2042, and a U.S. patent for its Delta Opioid Receptor Antibody Drug Conjugate technology running through 2043, both before any patent term extension.
- Clinical data: Preliminary results from the open-label IFx-2.0 study showed major objective partial responses in each of the first three patients, with all responses ongoing for more than six months, according to the filing.
TuHURA Biosciences Q3 2026 Financial Results and Program Update
TuHURA Biosciences, Inc. (NASDAQ:HURA), described in the filing as "a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy," reported third-quarter 2026 results on November 13, 2026. The company disclosed cash and cash equivalents of $1.9 million at September 30, 2026, and noted that the Parkview loan facility contributed $5.6 million in non-dilutive financing during the quarter. Net cash outflows from operating activities were ($18.1) million for the nine months ended September 30, 2026, compared to ($22.1) million for the same period in 2025. Net cash flows from financing activities were $16.5 million for the nine months ended September 30, 2026, versus $13.4 million for the nine months ended September 30, 2025.
On the clinical side, the filing states that preliminary data from an open-label front-line study of IFx-2.0 combined with Keytruda showed major objective partial responses in each of the first three patients in a deep-seated metastatic Merkel Cell Carcinoma study, with all responses ongoing for more than six months. The company also reported receiving FDA clearance to begin a Phase 1b study of TBS-2025 in patients with relapsed/refractory mutNPM1 AML who have failed to respond to or relapsed after Menin inhibitor therapy. According to the filing, if TBS-2025 results in encouraging response rates during the dose-optimization stage, the company plans to explore potential expansion of the trial with the FDA in consideration for accelerated approval.
The company disclosed three poster presentations scheduled at the 68th American Society of Hematology Annual Meeting and Exposition, taking place December 12-15, 2026, in New Orleans. The posters focus on the role of the Delta Opioid Receptor in controlling the immunosuppressive capabilities of myeloid-derived suppressor cells. The filing notes that the $50 million credit facility from the company's largest shareholder has allowed operations to be funded in what the company characterized as a "non-dilutive manner." The filing contains forward-looking statements regarding anticipated milestones, which are the company's own and subject to its cautionary language.
What Was Disclosed
TuHURA Biosciences filed a Q3 2026 financial results press release covering the quarter ended September 30, 2026. The disclosure included income statement line items, cash balances, share count, two new U.S. patents, FDA IND clearance for TBS-2025, and preliminary clinical data for IFx-2.0.



Please wait processing your request...